EGLE THERAPEUTICS
Egle Therapeutics is an emerging biotechnology company focused on developing First-In-Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases. The company was founded in 2020 and is based in Paris, France.
EGLE THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2020-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.egle-tx.com
Total Employee:
11+
Status:
Active
Contact:
+33-186640857
Email Addresses:
[email protected]
Total Funding:
40 M EUR
Technology used in webpage:
Microsoft Exchange Online
Similar Organizations
Immunscape AB
Immunscape is a privately held drug discovery focused on developing immunotherapies for cancer and autoimmune disease treatment.
Current Advisors List
Current Employees Featured
Founder
Investors List
Fund+
Fund+ investment in Series A - Egle Therapeutics
Takeda Ventures
Takeda Ventures investment in Series A - Egle Therapeutics
Life Sciences Partners
Life Sciences Partners investment in Series A - Egle Therapeutics
Bpifrance
Bpifrance investment in Series A - Egle Therapeutics
Bioqube Ventures
Bioqube Ventures investment in Series A - Egle Therapeutics
Official Site Inspections
http://www.egle-tx.com
- Host name: cluster020.hosting.ovh.net
- IP address: 46.105.57.169
- Location: Saint-Ouen France
- Latitude: 48.9067
- Longitude: 2.3339
- Timezone: Europe/Paris
- Postal: 93400
More informations about "Egle Therapeutics"
egle - Modulating Treg Cells to Balance Immunity
Paris, France, 5th May 2022 / Egle Therapeutics SAS (Egle), an emerging biotechnology company dedicated to developing novel immunotherapies for oncology and autoimmune …See details»
Egle Therapeutics - Crunchbase Company Profile
Oct 22, 2021 Contact Email [email protected] Phone Number +33-186640857 Egle Therapeutics is an emerging biotechnology company focused on developing First-In-Class immunotherapies targeting immune suppressor …See details»
Egle Therapeutics - LinkedIn
Egle Therapeutics is thrilled to announce its upcoming participation to the Society for Immunotherapy of Cancer (SITC) in Houston from Nov 6 to 10. Do not miss the opportunity to …See details»
EGL-001 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 29, 2024 Egle is evaluating its most advanced drug candidate in oncology, EGL-001 (a Treg-selective anti-CTLA4-IL-2m), in a Phase I/II clinical trial. In auto-immunity, Egle aspires to …See details»
Egle Therapeutics SAS - Drug pipelines, Patents, Clinical trials
Egle is evaluating its most advanced drug candidate in oncology, EGL-001 (a Treg-selective anti-CTLA4-IL-2m), in a Phase I/II clinical trial. In auto-immunity, Egle aspires to advance toward …See details»
Egle - Overview, News & Similar companies | ZoomInfo.com
May 9, 2024 Egle contact info: Phone number: +33 186640857 Website: www.egle-tx.com What does Egle do? Egle, a biotechnology company that focuses on developing immunotherapies …See details»
Egle Therapeutics - VentureRadar
Mar 2, 2021 Egle Therapeutics has assembled a proprietary translational based target discovery engine leveraging patient samples to map out - at the single cell level - unique transcriptomic …See details»
Egle Therapeutics - PitchBook
Egle Therapeutics General Information Description. Operator of a biotechnology company intended to develop immunotherapies for oncology and autoimmune diseases. The company develops a proprietary Treg (T cells) modulating drug …See details»
Egle Therapeutics - EQT Group
Dec 13, 2024 Egle is developing a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Treg starving ... Fund. LSP 7. Entry. 2021. Web. egle-tx.com. Sector. Healthcare. …See details»
Egle Therapeutics Company Profile - Office Locations ... - Craft
Egle Therapeutics has 5 employees at their 1 location and $46.4 m in total funding,. See insights on Egle Therapeutics including office locations, competitors, revenue, financials, executives, …See details»
EGLE Therapeutics Strengthens its Board of Directors with the ...
Egle aspires to advance toward the clinic its most advanced drug candidates, EGL-001 (a potential best-in-class Treg-selective anti-CTLA4-IL-2m) and EGL-003 (non-targeted IL-2 Treg …See details»
Egle Therapeutics - EU-Startups
Egle Therapeutics is an emerging biotechnology company focused on developing First-In-Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and …See details»
Egle Therapeutics Company Information - Funding, Investors, and …
Egle Therapeutics, based in Paris, is developing advanced immunotherapies for cancer and autoimmune diseases. Unlike traditional treatments, which often have severe side effects and …See details»
Une nouvelle stratégie en immunothérapie : l’Institut Curie salue la ...
Oct 19, 2021 Egle Therapeutics (Tx) est née des travaux d’Eliane Piaggio, directrice de recherche Inserm à l’Institut Curie où elle dirige l'équipe Immunothérapie Translationnelle, et …See details»
Egle Therapeutics Raises 40 Million - Business Wire
Oct 22, 2021 www.egle-tx.com. About LSP. LSP is one of the largest European investment firms providing financing for life sciences and health care companies. LSP’s management has …See details»
Company Information - RocketReach
Egle Therapeutics employs 33 employees. The Egle Therapeutics management team includes Luc Boblet (Founder and CEO), Pierre ... egle-tx.com; 3 267546XXXX; 610647XXXX; …See details»
EGL-003 - Drug Targets, Indications, Patents - Synapse
1 day ago Egle is evaluating its most advanced drug candidate in oncology, EGL-001 (a Treg-selective anti-CTLA4-IL-2m), in a Phase I/II clinical trial. In auto-immunity, Egle aspires to …See details»
New Fund+ portfolio company ! Egle Tx raises 40 million - LinkedIn
Oct 22, 2021 The key element of Egle’s core approach is the leveraging of itstranslational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed ...See details»
Egle Therapeutics Identifies First Novel Regulatory T-cell Targets in ...
Nov 26, 2020 The key element of Egle’s core approach is the leveraging of its translational-based target discovery engine to unveil novel therapeutic Treg targets and vectorize …See details»
Egle Therapeutics任命Monica Gostissa博士为首席科学官，Reno …
Mar 28, 2024 Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary …See details»